A prospective, multicenter, single-arm, open-label, phase 3 study of Lanreotide Autogel (LAN) in Chinese patients with unresectable, locally advanced or metastatic grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

#3700

Introduction: The efficacy of LAN has been demonstrated for the treatment of GEP-NETs and associated symptoms in Caucasian (CLARINET; NCT00353496) and Japanese patients but is yet to be explored in the Chinese population.

Aim(s): Evaluate efficacy and safety of LAN in Chinese patients with GEP-NETs.

Materials and methods: Chinese patients with GEP-NETs received LAN 120mg/28 days for 48 weeks (wks). The primary efficacy endpoint was clinical benefit rate (CBR; proportion of patients with a best overall response of confirmed complete response, confirmed partial response, or continued stable disease) at Wk24, assessed using RECIST 1.1 and confirmed by blinded independent central review. Key secondary efficacy endpoints at Wk24 (overall response rate [ORR], progression-free survival [PFS]) and adverse events (AEs; up to Wk24) are also reported.

Conference:

Presenting Author:

Authors: Lu M, Li E, Cao D, Chen J, Zhang N,

Keywords: neuroendocrine, neuroendocrine tumor, efficacy, safety,